Ignite Creation Date:
2024-05-06 @ 6:30 PM
Last Modification Date:
2025-12-16 @ 6:08 PM
Study NCT ID:
NCT05689203
Status:
None
Last Update Posted:
2023-01-19 00:00:00
First Post:
2023-01-15 00:00:00
Brief Title:
A Phase 2 Study to Evaluate the Efficacy and Safety of QLS1128 Orally in Symptomatic Participants With Mild to Moderate COVID-19
Sponsor:
Organization:
Qilu Pharmaceutical Co., Ltd.
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
360
Enrollment Type:
ESTIMATED
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: